Vicenin

Vicenin is a C-glycosylflavone — primarily found in holy basil, chamomile, and fenugreek — that exerts antioxidant, anti-inflammatory, and anti-cancer effects by scavenging free radicals and inhibiting key metabolic enzymes such as α-glucosidase and PTP1B. Its C-glycosidic bond at the flavone backbone confers greater metabolic stability compared to O-glycosylflavones, enhancing bioavailability and biological activity.

Origin & History

Vicenin-2, a flavonoid glycoside, is primarily found in medicinal plants like Ocimum sanctum and Artemisia capillaris. It is extracted using ethanol from aerial parts or whole herbs, though specific methods are not detailed beyond general extraction techniques.

Historical & Cultural Context

Vicenin-2 is an active component of Ocimum sanctum, utilized in Ayurvedic medicine for its radioprotective and anti-inflammatory properties. Despite its presence in traditional formulations, specific historical uses of vicenin-2 itself are not documented.

Health Benefits

• Exhibits anti-proliferative effects in prostate cancer models, reducing tumor size significantly in preclinical studies (PMID: 21803027). • Demonstrates anti-diabetic properties by inhibiting α-glucosidase and PTP1B (PMID: 24713265). • Reduces high-glucose-induced vascular inflammation in endothelial cells (PMID: 26766560). • Shows anti-inflammatory activity, evidenced by 41.5% reduction in rat paw edema (PMID: 21608987). • Provides relief from skin photoaging, as seen in unspecified model studies (PMID: 39923642).

How It Works

Vicenin inhibits α-glucosidase and protein tyrosine phosphatase 1B (PTP1B), two enzymes central to postprandial glucose regulation and insulin signaling, producing anti-diabetic effects at the molecular level. In prostate cancer models, it induces apoptosis and suppresses tumor proliferation by modulating cell cycle arrest pathways, likely involving caspase activation and downregulation of anti-apoptotic Bcl-2 proteins. Against vascular inflammation, vicenin attenuates high-glucose-induced NF-κB signaling in endothelial cells, reducing downstream expression of pro-inflammatory cytokines and adhesion molecules.

Scientific Research

No human clinical trials or meta-analyses are available for vicenin-2; all evidence is based on preclinical in vitro and in vivo studies. Notable studies include anti-cancer effects in prostate cancer cell lines and mouse models (PMID: 21803027), and anti-inflammatory effects in rat models (PMID: 21608987).

Clinical Summary

Current evidence for vicenin is derived almost entirely from in vitro cell studies and rodent preclinical models, with no published human clinical trials as of 2024. In prostate cancer cell line experiments (PMID: 21803027), vicenin significantly reduced tumor cell proliferation and tumor size in xenograft mouse models, though human translational data are absent. Anti-diabetic activity has been demonstrated through enzyme inhibition assays showing IC50 values in the micromolar range against α-glucosidase and PTP1B (PMID: 24713265). The overall evidence base is promising but remains at an early preclinical stage, requiring randomized controlled trials to establish efficacy and safe dosing in humans.

Nutritional Profile

Vicenin is a naturally occurring C-glycosyl flavone (specifically a di-C-glycoside of apigenin, also known as vicenin-2 in its most studied form: apigenin 6,8-di-C-glucoside), not a macronutrient-containing food ingredient but a purified bioactive phytochemical compound. It is found in herbs such as holy basil (Ocimum sanctum), parsley, celery, and various Apiaceae family plants, as well as in some citrus species. As a pure compound, it contains no protein, fat, or fiber. Molecular weight: approximately 594.52 g/mol (vicenin-2). Typical concentrations in source plants: 0.1–2.5 mg/g dry weight in Ocimum sanctum leaves; trace to 1.8 mg/g in parsley and celery. Bioactive compound classification: polyphenol, subclass flavone, C-glycoside. The C-glycosidic bonds (at C-6 and C-8 positions of the apigenin backbone) confer notable metabolic stability compared to O-glycosides, as these bonds resist hydrolysis by intestinal glycosidases and acid conditions, resulting in the intact glycoside reaching the colon where microbial fermentation may liberate the aglycone apigenin. Oral bioavailability is moderate to low (estimated <10–20% as intact compound); colonic microbiota-mediated transformation is the primary absorption route. No significant vitamin or mineral content is associated with vicenin as an isolated compound. Water solubility is relatively higher than its aglycone apigenin due to the sugar moieties, aiding formulation. No caloric value is attributed in pharmacological doses typically studied (1–100 µM in vitro; 10–50 mg/kg in preclinical in vivo models).

Preparation & Dosage

In preclinical prostate cancer studies, vicenin-2 was dosed at 1 mg/kg orally in mice. Human dosages have not been clinically studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Docetaxel, Apigenin, Curcumin, Resveratrol, Quercetin

Safety & Interactions

No human clinical trials have established a formal safety profile, tolerable upper intake level, or therapeutic dosage range for isolated vicenin supplementation. Because vicenin inhibits PTP1B and α-glucosidase, concurrent use with anti-diabetic drugs such as metformin, sulfonylureas, or acarbose may theoretically produce additive hypoglycemic effects, warranting caution. Potential interactions with anticoagulants or CYP450-metabolized drugs cannot be ruled out given the known flavonoid class effects on drug-metabolizing enzymes. Vicenin should be avoided during pregnancy and lactation due to a complete absence of safety data in these populations.